Ethylene Glycol

Ethylene Glycol

SCHEMBL5225335

COOOC.OCCO

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4535492-A1 LOCAL HIGH-CONCENTRATION ELECTROLYTE, SECONDARY BATTERY, ELECTRONIC DEVICE, AND MOBILE APPARATUS Huawei Technologies Co., Ltd. (CN) 2025-04-09 EP disclosed
CN-117438648-A Local high-concentration electrolyte, secondary battery, electronic device, and mobile device 华为技术有限公司 2024-01-23 CN disclosed
WO-2024012244-A1 LOCAL HIGH-CONCENTRATION ELECTROLYTE, SECONDARY BATTERY, ELECTRONIC DEVICE, AND MOBILE APPARATUS 华为技术有限公司 2024-01-18 WO disclosed
CN-114957564-A Bioactive coating 生物相互作用有限公司 2022-08-30 CN disclosed
US-20210130552-A1 REVERSIBLE METALLOPOLYMER NETWORK COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2021-05-06 US disclosed
US-10875970-B2 Reversible metallopolymer network COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2020-12-29 US disclosed
US-20200087463-A1 REVERSIBLE METALLOPOLYMER NETWORK COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2020-03-19 US disclosed
CN-110776610-A Bioactive coating 生物相互作用有限公司 2020-02-11 CN disclosed
CN-105517585-B Bioactivity coatings 生物相互作用有限公司 2019-11-22 CN disclosed
US-20170158824-A1 REVERSIBLE METALLOPOLYMER NETWORK COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2017-06-08 US disclosed
EP-1379525-B1 HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS NPS PHARMA INC (US) 2007-10-10 EP disclosed
US-7112595-B2 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists NPS PHARMACEUTICALS, INC. (US) 2006-09-26 US disclosed
US-20060189661-A1 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2006-08-24 US disclosed
EP-1679313-A2 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists NPS PHARMACEUTICALS, INC. (US) 2006-07-12 EP disclosed
US-20050154027-A1 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists NPS PHARMACEUTICALS, INC. 2005-07-14 US disclosed
EP-1379525-A2 HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS NPS PHARMACEUTICALS, INC. (US) 2004-01-14 EP disclosed
US-6660753-B2 For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease NPS PHARMACEUTICALS, INC. 2003-12-09 US disclosed
US-20030055085-A1 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2003-03-20 US disclosed
WO-2002068417-A3 HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS SLASSI ABDELMALIK (CA) 2002-11-14 WO disclosed
WO-2002068417-A2 HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS NPS PHARMACEUTICALS, INC. (US) 2002-09-06 WO disclosed